Actr-71. Phase 1/2 Study of Dianhydrogalactitol (Val-083) With Radiation Therapy in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma

Chen, Zhongping; Guo, Chengcheng; Bacha, Jeffrey; Steinø, Anne; Langlands, John; Kwan, Claire; Kanekal, Sarath; Schwartz, Richard; Lopez, Lorena; Brown, Dennis

doi:10.1093/neuonc/noy148.101

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of TTFields to target and disrupt rapid cancer cell division at multiple phases of the cell cycle allows for combinations with other therapies for synergistic or additive effects [75]. Cell cycle inhibitors and agents targeting cell proliferation, migration, and DNA replication in combination with TTFields are under investigation [76,77]. The GBM tumor microenvironment has been characterized as being highly immunosuppressive [78].…”

Section: Discussionmentioning

confidence: 99%

Tumor Treating Fields in the Management of Patients with Malignant Gliomas

Ghiaseddin

Shin

Melnick

et al. 2020

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

This article is part of the Topical Collection on Neuro-oncology Keywords Tumor treating fields I CNS tumors I Malignant glioma I Glioblastoma I Alternating electric fields I Optune® Opinion statement Malignant gliomas remain a challenging cancer to treat due to limitations in both therapeutic and efficacious options. Tumor treating fields (TTFields) have emerged as a novel, locoregional, antineoplastic treatment modality with favorable efficacy and safety being demonstrated in the most aggressive type of malignant gliomas, glioblastoma (GBM). In 2 large randomized, controlled phase 3 trials, the addition of TTFields was associated with increased overall survival when combined with adjuvant temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM (ndGBM) and comparable overall survival compared with standard chemotherapy in patients with recurrent GBM (rGBM). TTFields target cancer cells by several mechanisms of action (MoA) including suppression of proliferation, migration and invasion, disruption of DNA repair and angiogenesis, antimitotic effects, and induction of apoptosis and immunogenic cell death. Having several MoAs makes TTFields an attractive modality to combine with standard, salvage, and novel treatment regimens (e.g., radiotherapy, chemotherapy, and immunotherapy). Treatment within the field of malignant gliomas is evolving to emphasize combinatorial approaches that work synergistically to improve patient outcomes. Here, we review the current use of TTFields in GBM, discuss MOA and treatment delivery, and consider the potential for its wider adoption in other gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%